EMEA-002934-PIP01-20

Table of contents

Key facts

Active substance
crisantaspase
Therapeutic area
Oncology
Decision number
P/0453/2021
PIP number
EMEA-002934-PIP01-20
Pharmaceutical form(s)
  • Solution for injection
  • Solution for infusion
Condition(s) / indication(s)
  • Treatment of acute lymphoblastic leukaemia
  • Treatment of lymphoblastic lymphoma
Route(s) of administration
  • Intramuscular use
  • Intravenous use
Contact for public enquiries
Jazz Pharmaceuticals Ireland Ltd.
E-mail: corporateaffairsmediainfo@jazzpharma.com
Telephone: +1 35316347800
Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating